Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19

Zou, Yulin; Meng, Zhe

doi:10.2147/jir.s329252

Cited by 14 publications

(11 citation statements)

References 53 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results are a significant difference in the levels of IL-17A from a gradual decrease among the different groups, a greater priority than the moderate and severe groups group, and moderate group higher than severe group, this is confirmed by Ghazavi et al, (2021), there are studies that indicated an increase in IL-17A in patients with SARS-CoV-2 [20], but they did not indicate the type of severity such as: [21,22,23].…”

Section: Role Of Il-17a In Severity Sars-cov-2mentioning

confidence: 89%

Role of some interleukins in SARS-CoV-2 severity

2022

pnr

View full text Add to dashboard Cite

This study was established to detect some of the immune parameters changes that accompany Patients with SARS-CoV-2 who have varying degrees of illness severity, by targeting three groups of mild, moderate and severe cases of patients, while the fourth group was healthy volunteers as well as unvaccinated and it represents the group we took 20 samples from each of these four groups, and we performed the following tests for them: IL-1β, IL-17A and IL-18.In mild case: According to the study's findings, there has been a considerable rise, (p≤0.01) in the levels of IL1β, IL-17A and IL-18 in SARS-CoV-2 patients group when compared with healthy group.In moderate case: The results of this study found a high significant increase (p≤0.01) in levels of IL1β, IL-17A and IL-18 in SARS-CoV-2 patients group when compared with healthy group, healthy group, but IL-17A level lower than in moderate case compared with mild case.In severe case: The results of this study found a high significant increase (p≤0.01) levels of IL1β, IL-17A and IL-18 in SARS-CoV-2 patients group when compared with healthy group, but IL-17A level lower than in moderate case compared with mild case and moderate case.

show abstract

Section: Role Of Il-17a In Severity Sars-cov-2mentioning

confidence: 89%

Role of some interleukins in SARS-CoV-2 severity

2022

pnr

View full text Add to dashboard Cite

show abstract

“…The KEGG human analysis also mentions viral protein interaction with cytokine and cytokine receptor, PI3K-Akt, TNF signaling pathway and IL-17 substance. Among them, the IL-17 pathway has been observed to upregulate expression in the serum of COVID-19 patients in multiple studies and has been speculated to induce a cytokine storm to promote inflammation, while its inhibitors have been observed to attenuate or even prevent cytokine storms (40). This process has also been reported in the pathogenesis of AH, through intermediate monocytes expansion, functional activation, induction of CD4 T cell IL-17 expression, and enrichment in the liver of AH patients to obtain greater phagocytic capacity (41).…”

Section: Discussionmentioning

confidence: 99%

Exploration of the Link Between COVID-19 and Alcoholic Hepatitis from the Perspective of Bioinformatics and Systems Biology

Huang¹,

Yu²,

Zhou³

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been suggested to purpose threats to health of mankind. Alcoholic hepatitis (AH) is a life-threatening acute and chronic liver failure that takes place in sufferers who drink excessively. During the epidemic, AH has an increasing incidence of severe illness and mortality. However, for these two diseases, the intrinsic relationship of molecular pathogenesis, as well as common therapeutic strategies are still poorly understood. Methods: The transcriptome of the COVID-19 and AH has been compared to obtain the altered genes and hub genes were screened out through protein-protein interaction (PPI) network analysis. Via gene ontology (GO), pathway enrichment and transcription regulator analysis, a deeper appreciation of the interplay mechanism between hub genes were established. Results: With 181 common differentially expressed genes (DEGs) of AH and COVID-19 were obtained, 10 hub genes were captured. Follow-up studies located that these 10 genes typically mediated the diseases occurrence by regulating the activities of the immune system. Other results suggest that the common pathways of the two ailments are enriched in regulating the function of immune cells and the release of immune molecules. Conclusion: This study reveals the common pathogenesis of COVID-19 and AH and assist to discover necessary therapeutic targets to combat the ongoing pandemic induced via SARS-CoV-2 infection and acquire promising remedy strategies for the two diseases.

show abstract

“…22,41 The expression of PSORS1C1 gene regulate the secretion of IL-17, 42 and IL-17 inhibitors for the treatment of psoriasis and RA are considered to be a promising therapeutic option to terminate COVID-19. 43 CRHR1 , gene of receptor binding, is associated with the efficacy of corticosteroids. 44 Consistently, an open-label randomized controlled trial showed that taking dexamethasone, a corticosteroid, may lower the risk of 28-day mortality by 17% COVID-19-hospitalized patients.…”

Section: Discussionmentioning

confidence: 99%

Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: genome-wide cross trait analysis and bi-directional Mendelian randomization study

Yao

Wang

Guo

et al. 2022

Preprint

View full text Add to dashboard Cite

COVID-19 may cause a dysregulation of the immune system and has complex relationships with multiple autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). However, little is known about their common genetic architecture. We analysed summary-level genetic data from the latest COVID‐19 host genetics consortium and consortia on RA and SLE to examine the shared genetic etiology and causal relationship between COVID-19 and RA/SLE. The cross-trait meta-analysis identified 46, 47, and 19 shared genetic loci for severe COVID-19, COVID-19 hospitalization, and SARS-CoV-2 infection with RA, and 19, 24, and 11 shared loci with SLE, respectively. Shared genes were significantly enriched in the spleen, lung, whole blood, and small intestine, and involved in immune function, inflammation and coagulation process. Co-localization analysis identified eight shared loci in TYK2, IKZF3, COL11A2, PSORS1C1, MANEAL and COG6 genes for COVID-19 with RA, and four in CRHR1, FUT2 and NXPE3 genes for COVID-19 with SLE. Bi-directional Mendelian randomization analysis suggested RA is associated with a higher risk of COVID-19 hospitalization, and COVID-19 is not related to RA or SLE. Our novel findings improved the understanding of the common genetic aetiology shared by COVID-19, RA and SLE, and suggested an increased risk of COVID-19 hospitalization in people with higher genetic liability to RA.

show abstract

Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19

Cited by 14 publications

References 53 publications

Role of some interleukins in SARS-CoV-2 severity

Role of some interleukins in SARS-CoV-2 severity

Exploration of the Link Between COVID-19 and Alcoholic Hepatitis from the Perspective of Bioinformatics and Systems Biology

Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: genome-wide cross trait analysis and bi-directional Mendelian randomization study

Contact Info

Product

Resources

About